Poly Medicure · NSE: POLYMED · BSE: 531768

Q1 FY26 results · Apr–Jun 2025

Poly Medicure reported revenue from operations of ₹403.21 crore (up 4.8% from Q1 FY25) and net profit of ₹93.08 crore (up 25.7% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue from operations403.21384.78+4.8%440.83−8.5%
Other income41.6916.92+146.4%24.31+71.5%
Total income444.90401.70+10.8%465.14−4.4%
Profit before share of associates & JVs and tax121.6298.02+24.1%120.57+0.9%
Share of profit/(loss) of associates & JVs1.320.432.28
Net profit for the period93.0874.04+25.7%91.83+1.4%
EPS, basic (₹)9.197.71+19.2%8.92+3.0%
Net margin (%)23.119.220.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue from operations384.05367.42+4.5%420.97−8.8%
Other income41.1016.83+144.2%23.95+71.6%
Total income425.14384.26+10.6%444.92−4.4%
Profit before tax117.0696.08+21.8%116.50+0.5%
Net profit for the period87.9372.30+21.6%86.66+1.5%
EPS, basic (₹)8.687.53+15.3%8.40+3.3%
Net margin (%)22.919.720.6
Consolidated
Filed with BSE
08 Aug 2025, 17:49 IST
Board meeting
08 Aug 2025
Period
01 Apr 2025 to 30 Jun 2025
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
08 Aug 2025, 17:49 IST
Board meeting
08 Aug 2025
Period
01 Apr 2025 to 30 Jun 2025
Review status
Unaudited
Source
XBRL filing on BSE